Protalix BioTherapeutics
PLX
PLX
34 hedge funds and large institutions have $6.39M invested in Protalix BioTherapeutics in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more ownership
Funds ownership: →
more funds holding
Funds holding: →
16% less capital invested
Capital invested by funds: $7.6M → $6.39M (-$1.21M)
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
Holders
34
Holding in Top 10
–
Calls
$149K
Puts
$2K
Top Buyers
| 1 | +$2.66M | |
| 2 | +$28K | |
| 3 | +$17K | |
| 4 |
Goldman Sachs
New York
|
+$16K |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$2.6K |
Top Sellers
| 1 | -$383K | |
| 2 | -$319K | |
| 3 | -$276K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$173K |
| 5 |
Renaissance Technologies
New York
|
-$116K |